Sun Pharma has partnered up with Bayer to market Finerenone, a drug for chronic kidney disease, in India. Bayer grants non-exclusive rights to Sun Pharma to distribute Finerenone under the brand name Lyvelsa. Sun Pharma CEO emphasizes commitment to providing innovative medicines to Indian patients.
India Business News: Sun Pharma and Bayer have entered into an agreement to market and distribute a second brand of the patented medicine Finerenone in India. Finerenone i
Dr George Bakris reviews the clinical trial data for finerenone and provides insights on treatment selection, including the potential benefits of combination therapy with finerenone and SGLT2 inhibitors, in managing diabetic kidney disease.
Drs Diana Isaacs and Natalie Bellini emphasize the need for early detection of diabetic kidney disease through the monitoring of cardiometabolic risk factors.
Denmark: A recent study in Diabetes, Obesity and Metabolism has reported the potential benefit of finerenone for delaying the progression of non-proliferative diabetic retinopathy (NPDR) and.